Related Experiment Video
Updated: May 21, 2026

SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
Changes in the Proteasome Pool during Malignant Transformation of Mouse Liver Cells
T M Astakhova1, G V Delone, Yu V Lyupina
1Koltsov Institute for Developmental Biology, Russian Academy of Sciences.
Abstract:
Multiple forms of proteasomes regulate cellular processes by destroying proteins or forming the peptides involved in those processes. Various pathologies, including carcinogenesis, are related to changes in the functioning of the proteasome forms. In this study, we looked at the changes in the pool of liver proteasomes during nodular regenerative hyperplasia and formation of adenoma and hepatocellular carcinoma in mice treated with Dipin, followed by partial liver resection. The relative content of various proteasome forms was determined using Western blot analysis. The chymotrypsin-like activity of proteasomes was assessed from the hydrolysis of the commercial Suc-LLVY-AMC substrate. It was found that changes in the proteasome pool appeared already during the formation of diffuse nodules, the changes being the increased expression of the X(β5) constitutive subunit and the LMP7(β5i) and LMP2(β1i) immune subunits, accompanied by the increase of the total proteasome pool and the decrease in the chymotrypsin-like activity. These changes were more pronounced in hepatocellular carcinoma. The content of the total proteasome pool and the LMP2(β1i) immune subunit and the chymotrypsin-like activity in adenoma were intermediate compared to those in the samples of liver with diffuse nodules and carcinoma. In addition, the level of the Rpt6 subunit present in the 19S proteasome activator was increased in carcinoma. Our results indicate that nodular regenerative hyperplasia and adenomatosis may be stages preceding carcinogenesis. We also conclude that there is a need to find signalling pathways that change the expression of various proteasome subunits during carcinogenesis. The 19S proteasome activator, which is overexpressed in malignant tumours, can be a promising target for the development of new anticancer drugs.
Insights
Changes in liver proteasome forms, including increased expression of specific subunits, occur during early stages of liver disease and cancer development. The 19S proteasome activator may be a target for new anticancer drugs.
Area of Science:
- Cell Biology
- Biochemistry
- Oncology
Background:
- Proteasomes are crucial for protein degradation and peptide formation, regulating cellular processes.
- Dysfunctional proteasomes are implicated in various pathologies, including carcinogenesis.
- Understanding proteasome alterations during liver disease progression is vital for identifying therapeutic targets.
Purpose of the Study:
- To investigate changes in liver proteasome forms during nodular regenerative hyperplasia, adenoma, and hepatocellular carcinoma development in mice.
- To analyze the expression of proteasome subunits and their enzymatic activity in relation to liver carcinogenesis.
- To identify potential therapeutic targets for liver cancer based on proteasome alterations.
Main Methods:
- Western blot analysis to determine the relative content of various proteasome forms.
- Assay of chymotrypsin-like proteasome activity using the Suc-LLVY-AMC substrate.
- Induction of liver pathologies using Dipin treatment followed by partial liver resection in mice.
Main Results:
- Proteasome pool alterations were observed early in nodular regenerative hyperplasia, with increased expression of constitutive (X/β5) and immune (LMP7/β5i, LMP2/β1i) subunits.
- Total proteasome pool increased, while chymotrypsin-like activity decreased during disease progression, with more pronounced changes in hepatocellular carcinoma.
- The 19S proteasome activator subunit Rpt6 was elevated in carcinoma, suggesting its role in malignant transformation.
Conclusions:
- Nodular regenerative hyperplasia and adenomatosis represent pre-carcinogenic stages in liver disease.
- Signaling pathways influencing proteasome subunit expression during carcinogenesis require further investigation.
- The 19S proteasome activator presents a promising therapeutic target for developing novel anticancer drugs.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure
The proteasome is an...

